Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free STE Stock Alerts

STERIS (STE) Competitors

STERIS logo
$228.75 +0.35 (+0.15%)
Closing price 07/31/2026 03:59 PM Eastern
Extended Trading
$229.00 +0.25 (+0.11%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

STE vs. BSX, EW, BDX, IDXX, and RMD

Should you buy STERIS stock or one of its competitors? MarketBeat compares STERIS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with STERIS include Boston Scientific (BSX), Edwards Lifesciences (EW), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), and ResMed (RMD).

How does STERIS compare to Boston Scientific?

Boston Scientific (NYSE:BSX) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Boston Scientific has a net margin of 17.50% compared to STERIS's net margin of 13.18%. Boston Scientific's return on equity of 19.36% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
Boston Scientific17.50% 19.36% 10.99%
STERIS 13.18%14.15%9.52%

89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 0.3% of Boston Scientific shares are owned by insiders. Comparatively, 1.1% of STERIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Boston Scientific has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, STERIS has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Boston Scientific currently has a consensus target price of $71.62, indicating a potential upside of 53.20%. STERIS has a consensus target price of $277.25, indicating a potential upside of 21.20%. Given Boston Scientific's higher probable upside, equities analysts clearly believe Boston Scientific is more favorable than STERIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boston Scientific
2 Sell rating(s)
5 Hold rating(s)
24 Buy rating(s)
0 Strong Buy rating(s)
2.71
STERIS
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Boston Scientific has higher revenue and earnings than STERIS. Boston Scientific is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$20.07B3.46$2.90B$2.4718.93
STERIS$5.94B3.76$782.30M$7.9328.85

In the previous week, Boston Scientific had 70 more articles in the media than STERIS. MarketBeat recorded 90 mentions for Boston Scientific and 20 mentions for STERIS. STERIS's average media sentiment score of 1.02 beat Boston Scientific's score of 0.56 indicating that STERIS is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Boston Scientific
33 Very Positive mention(s)
12 Positive mention(s)
16 Neutral mention(s)
19 Negative mention(s)
1 Very Negative mention(s)
Positive
STERIS
9 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Boston Scientific and STERIS tied by winning 8 of the 16 factors compared between the two stocks.

How does STERIS compare to Edwards Lifesciences?

STERIS (NYSE:STE) and Edwards Lifesciences (NYSE:EW) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Edwards Lifesciences has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STERIS$5.94B3.76$782.30M$7.9328.85
Edwards Lifesciences$6.07B8.18$1.07B$1.7449.52

STERIS has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

In the previous week, Edwards Lifesciences had 4 more articles in the media than STERIS. MarketBeat recorded 24 mentions for Edwards Lifesciences and 20 mentions for STERIS. Edwards Lifesciences' average media sentiment score of 1.29 beat STERIS's score of 1.02 indicating that Edwards Lifesciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
STERIS
9 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Edwards Lifesciences
19 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

STERIS presently has a consensus price target of $277.25, indicating a potential upside of 21.20%. Edwards Lifesciences has a consensus price target of $100.27, indicating a potential upside of 16.36%. Given STERIS's stronger consensus rating and higher possible upside, equities analysts plainly believe STERIS is more favorable than Edwards Lifesciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STERIS
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Edwards Lifesciences
0 Sell rating(s)
6 Hold rating(s)
17 Buy rating(s)
0 Strong Buy rating(s)
2.74

Edwards Lifesciences has a net margin of 15.43% compared to STERIS's net margin of 13.18%. Edwards Lifesciences' return on equity of 15.85% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
STERIS13.18% 14.15% 9.52%
Edwards Lifesciences 15.43%15.85%12.14%

94.7% of STERIS shares are owned by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are owned by institutional investors. 1.1% of STERIS shares are owned by company insiders. Comparatively, 0.3% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Edwards Lifesciences beats STERIS on 10 of the 16 factors compared between the two stocks.

How does STERIS compare to Becton, Dickinson and Company?

Becton, Dickinson and Company (NYSE:BDX) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Becton, Dickinson and Company pays an annual dividend of $4.20 per share and has a dividend yield of 2.5%. STERIS pays an annual dividend of $2.52 per share and has a dividend yield of 1.1%. Becton, Dickinson and Company pays out 106.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. STERIS pays out 31.8% of its earnings in the form of a dividend. Becton, Dickinson and Company has increased its dividend for 53 consecutive years and STERIS has increased its dividend for 20 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Becton, Dickinson and Company had 8 more articles in the media than STERIS. MarketBeat recorded 28 mentions for Becton, Dickinson and Company and 20 mentions for STERIS. Becton, Dickinson and Company's average media sentiment score of 1.19 beat STERIS's score of 1.02 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Becton, Dickinson and Company
18 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
STERIS
9 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

87.0% of Becton, Dickinson and Company shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 0.4% of Becton, Dickinson and Company shares are owned by company insiders. Comparatively, 1.1% of STERIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Becton, Dickinson and Company presently has a consensus price target of $180.93, suggesting a potential upside of 8.87%. STERIS has a consensus price target of $277.25, suggesting a potential upside of 21.20%. Given STERIS's stronger consensus rating and higher possible upside, analysts plainly believe STERIS is more favorable than Becton, Dickinson and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Becton, Dickinson and Company
1 Sell rating(s)
8 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.41
STERIS
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

STERIS has a net margin of 13.18% compared to Becton, Dickinson and Company's net margin of 5.33%. Becton, Dickinson and Company's return on equity of 15.37% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
Becton, Dickinson and Company5.33% 15.37% 7.11%
STERIS 13.18%14.15%9.52%

Becton, Dickinson and Company has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and Company$21.84B2.10$1.68B$3.9542.07
STERIS$5.94B3.76$782.30M$7.9328.85

Becton, Dickinson and Company has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, STERIS has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Summary

STERIS beats Becton, Dickinson and Company on 10 of the 19 factors compared between the two stocks.

How does STERIS compare to IDEXX Laboratories?

STERIS (NYSE:STE) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

IDEXX Laboratories has lower revenue, but higher earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STERIS$5.94B3.76$782.30M$7.9328.85
IDEXX Laboratories$4.30B10.25$1.06B$13.5841.17

STERIS presently has a consensus target price of $277.25, suggesting a potential upside of 21.20%. IDEXX Laboratories has a consensus target price of $749.00, suggesting a potential upside of 33.97%. Given IDEXX Laboratories' higher probable upside, analysts plainly believe IDEXX Laboratories is more favorable than STERIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STERIS
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
IDEXX Laboratories
0 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.60

94.7% of STERIS shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 1.1% of STERIS shares are owned by company insiders. Comparatively, 0.8% of IDEXX Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, IDEXX Laboratories had 2 more articles in the media than STERIS. MarketBeat recorded 22 mentions for IDEXX Laboratories and 20 mentions for STERIS. IDEXX Laboratories' average media sentiment score of 1.37 beat STERIS's score of 1.02 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
STERIS
9 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IDEXX Laboratories
15 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

STERIS has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

IDEXX Laboratories has a net margin of 24.63% compared to STERIS's net margin of 13.18%. IDEXX Laboratories' return on equity of 70.87% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
STERIS13.18% 14.15% 9.52%
IDEXX Laboratories 24.63%70.87%32.56%

Summary

IDEXX Laboratories beats STERIS on 12 of the 16 factors compared between the two stocks.

How does STERIS compare to ResMed?

ResMed (NYSE:RMD) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

ResMed pays an annual dividend of $2.40 per share and has a dividend yield of 1.1%. STERIS pays an annual dividend of $2.52 per share and has a dividend yield of 1.1%. ResMed pays out 23.1% of its earnings in the form of a dividend. STERIS pays out 31.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has raised its dividend for 13 consecutive years and STERIS has raised its dividend for 20 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and lower payout ratio.

ResMed currently has a consensus price target of $246.25, suggesting a potential upside of 16.49%. STERIS has a consensus price target of $277.25, suggesting a potential upside of 21.20%. Given STERIS's stronger consensus rating and higher possible upside, analysts plainly believe STERIS is more favorable than ResMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ResMed
0 Sell rating(s)
9 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.44
STERIS
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

ResMed has a net margin of 27.44% compared to STERIS's net margin of 13.18%. ResMed's return on equity of 25.35% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
ResMed27.44% 25.35% 18.69%
STERIS 13.18%14.15%9.52%

ResMed has higher earnings, but lower revenue than STERIS. ResMed is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResMed$5.15B5.96$1.40B$10.3720.38
STERIS$5.94B3.76$782.30M$7.9328.85

ResMed has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, STERIS has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

In the previous week, STERIS had 6 more articles in the media than ResMed. MarketBeat recorded 20 mentions for STERIS and 14 mentions for ResMed. ResMed's average media sentiment score of 1.20 beat STERIS's score of 1.02 indicating that ResMed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ResMed
10 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
STERIS
9 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

55.0% of ResMed shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 0.7% of ResMed shares are held by insiders. Comparatively, 1.1% of STERIS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

ResMed beats STERIS on 10 of the 19 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for STE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STE vs. The Competition

Export
MetricSTERISHealthcare Equipment & Supplies IndustryHealthcare SectorNYSE Exchange
Market Cap$22.29B$5.58B$6.86B$23.67B
Dividend Yield1.10%1.79%2.59%4.22%
P/E Ratio28.8523.11282.2731.00
Price / Sales3.7656.61581.5219.22
Price / Cash15.0332.5328.6018.73
Price / Book3.126.2910.934.76
Net Income$782.30M$151.15M$3.49B$1.07B
7 Day Performance4.58%1.01%-0.64%-0.34%
1 Month Performance4.96%4.43%-3.78%-0.53%
1 Year Performance0.91%2.35%61.99%19.19%

STERIS Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STE
STERIS
4.9128 of 5 stars		$228.75
+0.2%		$277.25
+21.2%		+0.9%$22.29B$5.94B28.8517,937
BSX
Boston Scientific
4.6009 of 5 stars		$45.56
+3.0%		$79.64
+74.8%		-55.6%$65.77B$20.07B19.0659,000
EW
Edwards Lifesciences
4.2417 of 5 stars		$83.21
+0.7%		$99.55
+19.6%		+8.7%$47.58B$6.07B47.8216,000
BDX
Becton, Dickinson and Company
4.5294 of 5 stars		$158.94
+1.7%		$180.29
+13.4%		-5.7%$43.08B$21.84B40.2472,000
IDXX
IDEXX Laboratories
4.151 of 5 stars		$556.20
+2.2%		$749.00
+34.7%		+4.4%$42.94B$4.30B40.9611,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:STE) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
“The unseen winner of the AI race” is not SpaceX
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel